Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Human Papillomavirus | Research article

microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer

Authors: Sunyoung Park, Jungho Kim, Kiyoon Eom, Sehee Oh, Sunghyun Kim, Geehyuk Kim, Sungwoo Ahn, Kwang Hwa Park, Dawn Chung, Hyeyoung Lee

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

One-third of cervical cancer patients are still diagnosed at advanced stages. The five-year survival rate is decreased in about 50% of advanced stage cervical cancer patients worldwide, and the clinical outcomes are remarkably varied and difficult to predict. One of the miRNAs known to be associated with cancer tumorigenesis is miR-944. However, the prognostic value of miR-944 in cervical cancer has not been fully investigated. The aim of this study was to analyze clinical significance and prognostic value of miR-944 in cervical cancer.

Methods

The expression levels of miR-944 were detected using quantitative reverse transcription polymerase chain reaction in five types of cervical cancer cell lines and 116 formalin-fixed paraffin-embedded (FFPE) cervical tissues. The association between the expression levels of miR-944 and prognostic value was analyzed using the Kaplan-Meier analysis and Cox proportional hazards model.

Results

The expression levels of miR-944 in cervical cancer tissues were significantly higher compared with those in normal tissues (P < 0.0001). Moreover, the expression levels of miR-944 in cervical cancer cell lines and FFPE tissues with human papillomavirus (HPV) infection were significantly higher compared to those without HPV infection (P < 0.01 and P = 0.02). High miR-944 expression was also markedly associated with bulky tumor size (P = 0.026), advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.042), and lymph node metastasis (P = 0.030). In particular, high miR-944 expression group showed shorter overall survival than the low miR-944 expression group in the advanced FIGO stage (84.4% vs. 44.4%, HR = 4.0, and P = 0.01).

Conclusions

These results suggest that miR-944 may be used as a novel biomarker for improving prognosis and as a potential therapeutic target.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.PubMedCrossRef
2.
McGuire S. World Cancer report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO press, 2015. Adv Nutr. 2016;7(2):418–9.PubMedPubMedCentralCrossRef
3.
zur Hausen H. Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta. 1996;1288(2):F55–78.PubMed
4.
Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461–84.PubMedCrossRef
5.
6.
Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 2014;1845(2):255–65.PubMedPubMedCentral
7.
Hebert SS, De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009;32(4):199–206.PubMedCrossRef
8.
Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.PubMedCrossRef
9.
Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, Wang Y. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009;24(4):652–7.PubMedCrossRef
10.
Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007;67(13):6031–43.PubMedCrossRef
11.
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–70.PubMedCrossRef
12.
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64(11):3753–6.PubMedCrossRef
13.
Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1(12):882–91.PubMed
14.
He Z, Xu H, Meng Y, Kuang Y. miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer. Biomed Pharmacother. 2017;88:902–10.PubMedCrossRef
15.
He H, Tian W, Chen H, Jiang K. MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer. Tumour Biol. 2016;37(2):1599–607.PubMedCrossRef
16.
Xie H, Lee L, Scicluna P, Kavak E, Larsson C, Sandberg R, Lui WO. Novel functions and targets of miR-944 in human cervical cancer cells. Int J Cancer. 2015;136(5):E230–41.PubMedCrossRef
17.
Powrozek T, Kuznar-Kaminska B, Dziedzic M, Mlak R, Batura-Gabryel H, Sagan D, Krawczyk P, Milanowski J, Malecka-Massalska T. The diagnostic role of plasma circulating precursors of miRNA-944 and miRNA-3662 for non-small cell lung cancer detection. Pathol Res Pract. 2017;213(11):1384–7.PubMedCrossRef
18.
Flores-Perez A, Marchat LA, Rodriguez-Cuevas S, Bautista VP, Fuentes-Mera L, Romero-Zamora D, Maciel-Dominguez A, de la Cruz OH, Fonseca-Sanchez M, Ruiz-Garcia E, et al. Suppression of cell migration is promoted by miR-944 through targeting of SIAH1 and PTP4A1 in breast cancer cells. BMC Cancer. 2016;16:379.PubMedPubMedCentralCrossRef
19.
Pan T, Chen W, Yuan X, Shen J, Qin C, Wang L. miR-944 inhibits metastasis of gastric cancer by preventing the epithelial-mesenchymal transition via MACC1/met/AKT signaling. FEBS Open Bio. 2017;7(7):905–14.PubMedPubMedCentralCrossRef
20.
Wen L, Li Y, Jiang Z, Zhang Y, Yang B, Han F. miR-944 inhibits cell migration and invasion by targeting MACC1 in colorectal cancer. Oncol Rep. 2017;37(6):3415–22.PubMedCrossRef
21.
Yang YC, Shyong WY, Chang MS, Chen YJ, Lin CH, Huang ZD, Wang HMT, Chen ML. Frequent gain of copy number on the long arm of chromosome 3 in human cervical adenocarcinoma. Cancer Genet Cytogenet. 2001;131(1):48–53.PubMedCrossRef
22.
Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CJLM, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.PubMedCrossRef
23.
zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92(9):690–8.PubMedCrossRef
24.
Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology. 2009;384(2):324–34.PubMedCrossRef
25.
McLaughlin-Drubin ME, Munger K. The human papillomavirus E7 oncoprotein. Virology. 2009;384(2):335–44.PubMedCrossRef
26.
Wang XH, Wang HK, Li Y, Hafner M, Banerjee NS, Tang S, Briskin D, Meyers C, Chow LT, Xie X, et al. microRNAs are biomarkers of oncogenic human papillomavirus infections. P Natl Acad Sci USA. 2014;111(11):4262–7.CrossRef
27.
Lajer CB, Garnaes E, Friis-Hansen L, Norrild B, Therkildsen MH, Glud M, Rossing M, Lajer H, Svane D, Skotte L, et al. The role of miRNAs in human papillomavirus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer. 2012;106(9):1526–34.PubMedPubMedCentralCrossRef
28.
Cancer Genome Atlas Research. N, Albert Einstein College of M, analytical biological S, Barretos Cancer H, Baylor College of M, Beckman Research Institute of City of H, Buck Institute for research on a, Canada's Michael smith genome sciences C, Harvard medical S, Helen FGCC et al: Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378–84.CrossRef
29.
Banister CE, Liu C, Pirisi L, Creek KE, Buckhaults PJ. Identification and characterization of HPV-independent cervical cancers. Oncotarget. 2017;8(8):13375–86.PubMedPubMedCentralCrossRef
30.
Ma J, Mannoor K, Gao L, Tan A, Guarnera MA, Zhan M, Shetty A, Stass SA, Xing L, Jiang F. Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing. Mol Oncol. 2014;8(7):1208–19.PubMedPubMedCentralCrossRef
31.
Wang C, Jiang T. MicroRNA-335 represents an independent prognostic marker in cervical cancer. Tumour Biol. 2015;36(8):5825–30.PubMedCrossRef
32.
Azizmohammadi S, Safari A, Azizmohammadi S, Kaghazian M, Sadrkhanlo M, Yahaghi E, Farshgar R, Seifoleslami M. Molecular identification of miR-145 and miR-9 expression level as prognostic biomarkers for early-stage cervical cancer detection. QJM. 2017;110(1):11–5.PubMedCrossRef
33.
Jiang W, Pan JJ, Deng YH, Liang MR, Yao LH. Down-regulated serum microRNA-101 is associated with aggressive progression and poor prognosis of cervical cancer. J Gynecol Oncol. 2017;28(6):e75.PubMedPubMedCentralCrossRef
34.
Christensen LL, Tobiasen H, Holm A, Schepeler T, Ostenfeld MS, Thorsen K, Rasmussen MH, Birkenkamp-Demtroeder K, Sieber OM, Gibbs P, et al. MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer. Int J Cancer. 2013;133(1):67–78.PubMedCrossRef
35.
Nordentoft I, Birkenkamp-Demtroder K, Agerbaek M, Theodorescu D, Ostenfeld MS, Hartmann A, Borre M, Orntoft TF, Dyrskjot L. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genet. 2012;5:40.
36.
Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 1999;18(53):7690–700.PubMedCrossRef
37.
Caldeira S, Dong W, Tommasino M. Analysis of E7/Rb associations. Methods Mol Med. 2005;119:363–79.
Metadata
Title
microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer
Authors
Sunyoung Park
Jungho Kim
Kiyoon Eom
Sehee Oh
Sunghyun Kim
Geehyuk Kim
Sungwoo Ahn
Kwang Hwa Park
Dawn Chung
Hyeyoung Lee
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5620-6

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Study protocol

Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study

Study protocol

A longitudinal mixed methods study on changes in body weight, body composition, and lifestyle in breast cancer patients during chemotherapy and in a comparison group of women without cancer: study protocol

Research article

Whole genome sequencing reveals complexity in both HPV sequences present and HPV integrations in HPV-positive oropharyngeal squamous cell carcinomas

Research article

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan

Research article

On the use of flexible excess hazard regression models for describing long-term breast cancer survival: a case-study using population-based cancer registry data

Research article

Thyroid Cancer in Ecuador, a 16 years population-based analysis (2001–2016)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits